Antiplatelet therapy for prevention of death, myocardial infarction, and stroke
17 results
1 - 17
Antiplatelet therapy for prevention of death, myocardial infarction, and stroke - Antithrombotic agents in primary health care
- Antiplatelet agents and anticoagulants for hypertension
- Cerebral infarction (ischaemic stroke)
Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack Edited (no change to conclusions)- Antiplatelet agents and anticoagulants for hypertension New search for studies and content updated (no change to conclusions)
- Low-dose aspirin for primary prevention of vascular events in type 2 diabetes
- Oral anticoagulants vs antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or TIA
- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin- Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
- Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment: Cochrane systematic review